Key result
Two-territory coronary testing in ANOCA cuts undiagnosed dysfunction by an absolute ~11% vs LAD-only assessment.
Why the study?
The diagnostic paradigm for angina with non-obstructive coronary arteries assumes vasomotor dysfunction is homogeneous and relies on single-vessel interrogation, but emerging evidence suggests pathology may be territory-specific.
Does two-territory invasive coronary function testing of both the LAD and RCA improve diagnostic yield and identify spatial heterogeneity of vasomotor dysfunction compared to a single-vessel LAD-only strategy in patients with ANOCA?
Observational (n=213)
Yes
Does two-territory invasive coronary function testing of both the LAD and RCA improve diagnostic yield and identify spatial heterogeneity of vasomotor dysfunction compared to a single-vessel LAD-only strategy in patients with ANOCA?
Answers are grounded in this paper and cite their sources.
In patients with ANOCA, coronary vasomotor dysfunction exhibits substantial spatial heterogeneity between the LAD and RCA (58.7% discordance), demonstrating that conventional single-vessel LAD assessment misses or misclassifies vasomotor phenotypes in nearly 30% of patients.
Background: The diagnostic paradigm for angina with non-obstructive coronary arteries assumes that vasomotor dysfunction is a global, homogeneous phenomenon, typically assessed via single-vessel interrogation. However, emerging evidence suggests that vascular pathology may be territory specific, potentially obscuring true patient-level pathophysiology and compromising clinical precision.
No takes yet. Share an insight, caveat, or question.
Hosokawa et al. (2026) conducted an observational in Angina with non-obstructive coronary arteries (ANOCA) (n=213). Two-territory coronary function assessment (LAD and RCA) vs. Single-vessel (LAD-only) coronary function assessment was evaluated on Classification of no identifiable coronary vasomotor dysfunction (ARR 10.8%, p=<0.001). Two-territory coronary assessment in ANOCA revealed diagnostic discordance in 58.7% of patients and reduced the rate of no identifiable dysfunction from 38.0% to 27.2% vs LAD-only testing.
Synapse has enriched 10 related papers. Consider them for comparative context: